17.47 USD
↘ 0.91 (4.95%)AT CLOSE (11:59 AM EDT)
Zenas BioPharma, Inc. Common Stock
ZBIONASDAQ • USD
17.51
↗ 0.04 (0.23%)
POST MARKET (AS OF 07:38 PM EDT)
Post Market
AS OF 07:38 PM EDT
17.51
↗ 0.04 (0.23%)
Market: CLOSED
Open?$18.33
High?$18.92
Low?$17.40
Prev. Close?$18.38
Volume?494.1K
Avg. Volume?544.4K
VWAP?$18.17
Rel. Volume?0.91x
Bid / Ask
Bid?$14.86 × 100
Ask?$21.16 × 100
Spread?$6.30
Midpoint?$18.01
Valuation & Ratios
Market Cap?1.1B
Shares Out?63.1M
Float?22.7M
Float %?39.5%
P/E Ratio?N/A
P/B Ratio?3.28
EPS?-$6.73
Dividend?0.00%
Ex-Dividend?N/A
Zenas BioPharma, Inc. Common Stock (ZBIO) trades at $17.47 per share. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. ZBIO is fairly valued relative to its sector peers based on current multiples.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Employees
167
Market Cap
1.1B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2024-09-13
Address
852 WINTER STREET, SUITE 250
WALTHAM, MA 02451
Phone: 857-271-2954
WALTHAM, MA 02451
Phone: 857-271-2954
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?1
Momentum?50
Short Sent.?30
Piotroski F-Score?0/9Weak
Altman Z-Score?-0.77Distress
Confidence?53%Low
Short InterestSqueeze Risk
Short % of Float?47.18%Squeeze Risk
Short Interest?10.7M
Days to Cover?21.3
Free Float22.7M
Avg Daily Volume501.4K
Settlement Date2026-05-15
Financial Health
Current Ratio?11.94Strong
Quick Ratio?11.94Strong
Cash Ratio?8.18Strong
Debt/Equity?0.79Moderate
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score83/100
P/E?N/A▾
P/B?3.28FAIR▾
Peers100
S&P52
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-2.1CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-126.6%WEAK▾
S&P3
ROA?-56.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-210480000
Enterprise Value?$868.4M
Fundamentals ratios updated end of day